Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
europe blog main
3
×
fda
life sciences
national
3
×
national blog main
national top stories
new york blog main
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
clinical trials
detroit blog main
detroit top stories
europe top stories
indiana blog main
indiana top stories
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
accent therapeutics
aducanumab
allergan
alzheimer's disease
amblyotech
amgen
arena pharmaceuticals
What
fda
3
×
medicines
new
activity
adults
allergan
approvals
approved
bio
biogen
cancer
clamped
class
covid
delays
developing
drug
economic
eisai
fast
flags
higher
incidence
including
ipo
isn’t
lorcaserin
loss
lot
market
marketing
medicine
migraine
monday
nod
oric’s
patients
pill
post
pulls
Language
unset
Current search:
national
×
" europe blog main "
×
fda
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
